Resverlogix obtains patents for RVX-208 in China

CALGARY, Alberta-based Resverlogix Corp. has received two China patent approvals covering RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor. 

 

The first, a composition of matter patent (China No. 2007 8 0052349.8) titled "Compounds for the Prevention and Treatment of Cardiovascular Disease," was granted until February 2027. The second is a manufacturing patent (China No. ZL 2009 8 0106586.7) titled "Methods of Preparing Quinazolinone Derivatives" granted until June 2029.

 

"These two additional patents build upon the growing intellectual property estate for our core asset, RVX-208. With our Chinese patent life extending out to June 2029, RVX-208 now has the necessary protection required for a regional licensing deal in China," said Donald McCaffrey, president and CEO of Resverlogix.

 

On April 15th, Resverlogix is one of four selected Canadian companies who will be presenting at China Bio.

 

"Resverlogix views the ever expanding Chinese pharmaceutical market as an attractive opportunity which aligns with our regional licensing strategy. We will continue our discussions with potential partners at the China Bio Partnering Forum in Shanghai next week," Mr. McCaffrey said.

 

RVX-208 is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with potentially important benefits for patients with diseases such as cardiovascular disease (CVD), diabetes mellitus (DM), Alzheimer's disease, peripheral artery disease, and chronic kidney disease while maintaining an excellent safety profile. 

 

Resverlogix is planning to study RVX-208 in a proposed Phase 3 clinical trial in CVD patients with DM and low HDL.